Supernus Pharmaceuticals SUPN Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's return on invested capital?
- Supernus Pharmaceuticals (SUPN) reported return on invested capital of -6.4% in Q1 2026.
- How has Supernus Pharmaceuticals's return on invested capital changed year-over-year?
- Supernus Pharmaceuticals's return on invested capital decreased by 218.5% year-over-year, from 5.4% to -6.4%.
- What is the long-term trend for Supernus Pharmaceuticals's return on invested capital?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's return on invested capital has grown at a -25.3% compound annual growth rate (CAGR), from 27.1% to -6.3%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.